<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382395</url>
  </required_header>
  <id_info>
    <org_study_id>SLX53</org_study_id>
    <nct_id>NCT00382395</nct_id>
  </id_info>
  <brief_title>SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma</brief_title>
  <official_title>Randomized, Controlled, Multicenter Comparative Trial to Evaluate the SOLX Gold Shunt for the Reduction of Intraocular Pressure (IOP) in Glaucomatous Eyes Following Failed Medical and Conventional Surgical Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOLX, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objective:

      To establish the substantial equivalence of the SOLX Gold Shunt to commercially available
      aqueous shunts, specifically the Ahmed™ Glaucoma Valve Model FP7, in the ability to reduce
      intraocular pressure (IOP) associated with glaucoma in eyes where medical and conventional
      surgical treatments have failed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is a randomized, controlled, multi-center, outpatient study to compare the IOP
      lowering ability and safety profile of the SOLX Gold Shunt to the selected, commercially
      available aqueous shunt product (i.e., Control shunt Model FP7 Ahmed™ Glaucoma Valve Flexible
      Plate™) for a period of up to one year. Extended follow up is scheduled for a period not to
      exceed two years, should this be necessary for regulatory purposes. Follow-up beyond one year
      will be expected unless other patients with SOLX Gold Shunt implants in earlier phase studies
      outside the US clearly show no significant adverse effects associated with the long-term use
      of the device for follow-up periods exceeding one year, and this information is deemed
      adequate to reduce the required follow-up period under this protocol to a shorter period,
      such as 6 months for the last-to-enter patients at the time of filing for 510(k) marketing
      clearance review with the FDA.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage reduction in IOP at both 12 and 24 months after implant</measure>
    <time_frame>1 &amp; 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute IOP</measure>
    <time_frame>1 &amp; 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of glaucoma medications</measure>
    <time_frame>1 &amp; 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate</measure>
    <time_frame>1 &amp; 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Open Angle</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOLX Gold Shunt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Ahmed FP7 Shunt</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SOLX Gold Shunt GMS-plus</intervention_name>
    <description>Single use implant</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ahmed FP7 Glaucoma Valve</intervention_name>
    <description>Single use implant</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary open-angle, pseudoexfoliative, or pigmentary glaucoma

          -  Age 21 or over

          -  refractory glaucoma, with IOP &gt;21 mmHg on medications and failed prior incisional
             glaucoma surgery

          -  detectable visual field defect (negative MD score)

          -  written consent

          -  available for up to 24 months follow-up

        Exclusion Criteria:

          -  either eye with VA worse than count fingers

          -  recent angle closure glaucoma episode

          -  uveitic glaucoma, iridocorneal endothelial (ICE) syndrome, traumatic glaucoma, or
             neovascular glaucoma

          -  other significant ocular disease, except cataract

          -  active ocular infection

          -  expected ocular surgery in next 12 months

          -  no suitable quadrant for implant

          -  systemic corticosteroid therapy &gt; 5 mg/day prednisone

          -  intolerance to gonioscopy or other eye exams

          -  mental impairment interfering with consent or compliance

          -  pregnancy

          -  known sensitivity to anticipated medications used at surgery

          -  significant co-morbid disease

          -  concurrent enrollment in another drug or device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan S. Peterson, MS, RAC</last_name>
    <role>Study Director</role>
    <affiliation>The EMMES Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Bay Eye Associates</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Consultants of Colorado</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Eye Care</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eagle Mountain Vision</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee / Hamilton Eye Institute</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley EyeCare</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5L 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut du Glaucome de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1V 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bombay City Eye Institute &amp; Research Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Research Foundation / Sankara Nethralaya</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Institute of the Health Services</name>
      <address>
        <city>Warsaw</city>
        <zip>09-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>India</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2006</study_first_submitted>
  <study_first_submitted_qc>September 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2006</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <name_title>Doug Adams</name_title>
    <organization>SOLX, Inc.</organization>
  </responsible_party>
  <keyword>Glaucoma shunt</keyword>
  <keyword>Ocular implant</keyword>
  <keyword>Gold</keyword>
  <keyword>trabeculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

